INCLUSION CRITERIA:

Patients must be diagnosed with biopsy-proven glioblastoma multiforme or anaplastic astrocytoma (WHO grade III and IV, WHO classification of glial tumors) and meet the following criteria:

Consenting males and females between the ages of 18 and 75, inclusive.

Provided written informed consent prior to participation in the trial.

Karnofsky Performance Scale Score greater than or equal to 60.

Patients of all races and sexes are eligible for this study. Children and adolescents only rarely are afflicted with gliomas that are amenable for surgical resection, and so are excluded from this study.

Patients who have been accepted for glioma resection under existing NINDS protocols are also eligible for this study.

If tumor tissue is available from biopsy prior to surgery, we will attempt to identify tumor-specific mutation(s) prior to enrolling the patient.

EXCLUSION CRITERIA:

Clinically unstable condition.

Liver function impairment (total bilirubin greater than 2.0 mg/dl; AST or ALT greater than 3 times the upper limit of normal).

Coagulopathy (prothrombin time [PT] or activated partial thromboplastin time [APTT] > 1.5 times control).

Thrombocytopenia (platelet count less than 100,000/mm3).

Granulocytopenia (absolute neutrophil count less than 1,000/mm3).

Acute infection.

Acute medical problems.

Positive HIV test.

Karnofsky Performance Scale Score less than 60.

Allergy to CT contrast agents.

Absence of tumor-specific gene mutation.

Pregnant women. Women of child-bearing potential will undergo a urine and/or serum pregnancy test. Women who are pregnant will not be allowed to participate in this study.